Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.

doi:10.1182/blood.2020007233

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.

Blood - 1 Apr 2021

Stein Eytan M, DiNardo Courtney D, Fathi Amir T, Mims Alice S, Pratz Keith W, Savona Michael R, Stein Anthony S, Stone Richard M, Winer Eric S, Seet Christopher S, Döhner Hartmut, Pollyea Daniel A, McCloskey James K, Odenike Olatoyosi, Löwenberg Bob, Ossenkoppele Gert J, Patel Prapti A, Roshal Mikhail, Frattini Mark G, Lersch Frederik, Franovic Aleksandra, Nabhan Salah, Fan Bin, Choe Sung, Wang Hongfang, Wu Bin, Hua Lei, Almon Caroline, Cooper Michael, Kantarjian Hagop M, Tallman Martin S

Abstract excerpt

Ivosidenib (AG-120) and enasidenib (AG-221) are targeted oral inhibitors of the mutant isocitrate dehydrogenase (mIDH) 1 and 2 enzymes, respectively. Given their effectiveness as single agents in mIDH1/2 relapsed or refractory acute myeloid leukemia (AML), this phase 1 study evaluated the safety and efficacy of ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed mIDH1/2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Pyridines

Share to Treatment Outcome

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 33024987
DOI: 10.1182/blood.2020007233
PMCID: PMC8020270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.PMID 33024987Read ↗

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.Semantic proximity Read ↗

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.Semantic proximity Read ↗

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.Semantic proximity Read ↗

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.Semantic proximity Read ↗

Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.Semantic proximity Read ↗

IDH Inhibitors in AML-Promise and Pitfalls.Semantic proximity Read ↗

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.Semantic proximity Read ↗

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: a real-world studySemantic proximity Read ↗

Evaluating ivosidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.